This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Neuronetics, Inc.
11/4/2026
Good day and thank you for standing by. Welcome to the Neuronetics Report's third quarter 2026 Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode. After the presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's call is being recorded. I would now like to hand the conference over to your first speaker today, Amin Patel with ICR Healthcare. Please go ahead.
Good morning, and thank you for joining us for the Neuronetics Third Quarter 2026 Conference Call. Joining me on today's call are the Neuronetics President and Chief Executive Officer, Dan Rivers, and Chief Financial Officer Nir Naor. Before we begin, I would like to caution listeners that certain information discussed by management during this conference call will include forward-looking statements related to our business strategy, financial and revenue guidance, and other operational issues and metrics. Actual results can differ materially from the company's business. For our discussion of risks and uncertainties associated with NeuroNetics business, I encourage you to review the company's filings, with the Securities and Exchange Commission, including the company's annual report on Form 10-K, which was filed in March, and the company's quarterly report on Form 10-Q for the quarter ending March 31, 2026. The company disclaims any obligation to update any forward-looking statement made during the course of this call, except as required by law. During the call, we will also discuss certain information on a non-GAAP basis, including EBITDA. Management believes that non-GAAP financial information taken in conjunction with US GAAP financial measures provides useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of trends in our operating results. Reconciliation between US GAAP and non-GAAP results are presented in the tables accompanying our press release which can be viewed on our website. With that, it's my pleasure to turn the call over to Neuronetics President and Chief Executive Officer, Dan Reuvers.
Thanks, Aman, and good morning, everyone. Thank you for joining us for our third quarter 2026 earnings call. I'll first walk you through the quarter, reviewing our results on each side of the business, and then I'll turn it over to Nir to discuss our financial results in greater detail. I'll then come back with how we're thinking about the rest of the year and the setup for 2027 before opening it up for questions. Turning to the quarter, we continued to execute against the profitability and operating cash goals we outlined earlier in the year, and we made meaningful progress on both fronts. Total revenue for the quarter was approximately $42 million, up over 12% versus the third quarter of last year. The results reflect a record quarter for Neurostar system sales, driven by a welcome reception from customers toward our expanded go-to-market strategy, as well as continued strength within our Greenbrook clinics as we realized ongoing impacts of our revenue cycle management efforts. Diving deeper into our Neurostar performance, let me start there. Total worldwide revenue was $15.8 million. up approximately 2% year-over-year. This was primarily driven by our capital equipment business, where we had a record quarter of system sales. We saw strong double-digit year-over-year performance here, and I believe it's being positively impacted by the go-to-market changes we introduced earlier this year. Notably, we believe many of these placements are with customers we would not have been able to compete for with our prior approach. including a recently awarded sole source agreement with a large national player. The strength of our capital business was partly offset by Sessions revenue being down versus last year, which was expected as we implement our new sales strategy. We continue to expect the overall revenue mix to be weighed more towards Neurostar Capital versus Sessions going forward as we execute on our plan. As such, we expect session revenue to continue to trend slightly downwards. We believe that our go-to-market changes position us well to compete in a broader segment of the market and expect to yield higher overall net growth in 2027 and beyond. It's also worth reiterating that for customers preferring our treatment session model built around a high-touch partnership with Neuronetics, nothing changes. We believe this sessions model continues to set us apart, as we believe we're uniquely equipped to help emerging TMS practices establish a profitable therapy adjunct. Neurostar customers perform almost twice as many treatments per chair as the competitive landscape, a velocity differentiator we believe directly reflects the support and affirmation of value we bring. During the quarter, we also had several noteworthy advances that reinforced our commitment to growing the Neurostar platform. On the regulatory front, in August, we submitted a 510 to the FDA for an accelerated TMS protocol, and it's currently under review. We expect that condensed protocols can be an advantage for some patients, and this could be another way to expand access to TMS for even more patients. We also had an important publication in the TMS Journal titled The Impact of Treatment Gaps on the Effectiveness of Transcranial Magnetic Stimulation in Major Depressive Disorder. The paper reflected analysis of over 6400 patients whose depression was treated with NeuroStar under real-world conditions. It showed that approximately 15% of patients completed their treatment course with no gaps leaving 85% of patients who missed one or more scheduled treatment days. Since missed days can be common, patients and physicians often wonder if a missed treatment day may negatively affect outcomes. The analysis found that there was no statistically significant difference in outcome between patients that experienced a gap in their treatment versus those that didn't. It further concluded that missing treatment for up to 13 days did not reduce effectiveness. This is an important consideration as patients may otherwise put off initiating treatment based on their availability to commit to an uninterrupted sequence of days. Lastly, we signed a distribution agreement with Wave Neuroscience to integrate its MERT system with Neurostar. MERT uses EEG data to personalize TMS protocols and received FDA clearance in June for treating adults with post-traumatic stress disorder, achieving 68% remission in its pivotal trial. Prior to launch, we plan to seek FDA clearance to add NeuroStar as a TMS system compatible with Wave Neuroscience's PTSD indication. Approximately nine million US adults experience PTSD annually, with an estimated four plus million of those seeking treatment. Thus, this partnership represents a significant opportunity to expand Neurostar's clinical application. On the operational front, we announced in September what we believe is the first ever integration between a TMS system and an electronic health record, or EHR, connecting our TrackStar practice management platform with advanced MD. a cloud-based EHR practice management and revenue cycle platform serving more than 65,000 practitioners across 13,000 independent practices, including our own Greenbrook clinics. Delivering TMS means coordinating care across a multi-session course of treatment, along with documentation and clinical notes, while claims and authorizations are often managed in separate systems. This creates duplicate work for practices. With this integration, treatment data flows into the same system where a practice manages its schedule, clinical records and notes, and revenue cycle. It'll be available in the fourth quarter to NeuroStar providers already using AdvancedMD. We use AdvancedMD as our EHR at our Greenbrook clinics, so we expect to benefit from this efficiency. just like our Neurostar customers. This inaugural integration further paves the way for us to integrate TrackStar into additional EHRs, extending additional practice efficiencies to Neurostar customers and prospects alike. Moving to GreenBrook. Revenue is approximately $26 million, up over 20% year over year. Our work on revenue cycle management continued to produce results with better patient qualification, cleaner claims, and more efficient collections, all helping us convert more of each billed dollar to cash. This quarter, we also began deploying SkyPoint, an AI-enabled coding optimization tool, which builds on automation technology established earlier this year. This advances the operational discipline we've been building throughout the organization by ensuring insurance claims are submitted quickly and accurately. We are very encouraged by the early results and believe there's still runway ahead for us. We continue to believe that filling the capacity in our existing clinics remains an important profitability lever. Our focus will continue to be on finding the most efficient ways to serve even more qualified patients that can benefit from our therapies. Two key measures that we monitor closely are relative return on our direct-to-consumer advertising and field sales team effectiveness. We determined, based on what we're seeing to date, that field sales personnel deliver the better return and give us more control over patient acquisition cost and yield. As a result, we're shifting a portion of our direct-to-consumer ad spend towards expanding our Green Brook field sales team. We expect this to sponsor a bigger sales team without increasing overall sales and marketing expense. We plan to begin this process in the fourth quarter. We expect the new reps to be fully ramped up and contribute meaningfully by mid-27. As we execute this strategy, we will update you on our progress. Overall, this quarter, we continue doing what matters most. executing against our new go-to-market strategy for Neurostar while competing for customers who were previously out of reach, running our Greenbrook clinics more efficiently, and delivering on our goals towards profitability and cash generation. With that, I'll turn it over to Nir to take you through the financials, and I'll come back with our outlook for the rest of the year. Nir?
You're reading a preview of the STIM Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing